ApoB: The Cholesterol Number Your Doctor Probably Is Not Ordering
LDL cholesterol has been the primary cardiovascular risk biomarker for 50 years. It remains useful - but it misses a critical dimension of risk that ApoB captures directly. ApoB counts the actual number of atherogenic particles in your bloodstream, not the cholesterol they carry. For a significant fraction of metabolically healthy adults, ApoB reveals cardiovascular risk that standard lipid panels completely miss.
- Every atherogenic lipoprotein particle - VLDL, IDL, LDL, Lp(a) - carries exactly one ApoB molecule. This means ApoB is a direct count of the total number of atherogenic particles in circulation, making it the most accurate single measure of cardiovascular risk from dyslipidemia.
- A substantial proportion of people with normal or even optimal LDL-C have elevated ApoB - a pattern called discordance. These individuals are at genuinely elevated cardiovascular risk that their LDL number conceals. Conversely, some people with modestly elevated LDL-C have low ApoB and low particle risk.
- The INTERHEART study found that the ApoB to ApoA1 ratio was the strongest lipid-based predictor of myocardial infarction across all populations studied - stronger than LDL-C, non-HDL cholesterol, or the total cholesterol to HDL ratio.
- The optimal ApoB target for longevity purposes is below 70 mg/dL. The standard lab reference range considers below 100 mg/dL acceptable - a threshold calibrated for average cardiovascular risk, not longevity optimization.
- ApoB is now measurable for under 20 dollars at most commercial labs without a physician order in most US states. It is one of the highest-value additions anyone can make to their longevity bloodwork panel.
The standard lipid panel - total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides - has been the cornerstone of cardiovascular risk assessment since the Framingham Heart Study established LDL cholesterol as a major risk factor in the 1960s. The panel is useful and widely accessible. It is also an indirect and sometimes misleading proxy for the actual biology driving cardiovascular disease: the number and size of atherogenic lipoprotein particles in circulation.1
LDL cholesterol measures the total amount of cholesterol carried by LDL particles. It does not measure how many LDL particles there are. This distinction matters because it is the particle - specifically its ApoB lipoprotein shell - that penetrates the arterial wall and initiates the atherosclerotic process, not the cholesterol inside it. Two people can have identical LDL cholesterol values but dramatically different particle counts - and dramatically different cardiovascular risk.
What ApoB Actually Measures
Apolipoprotein B (ApoB) is the primary structural protein of every atherogenic lipoprotein particle: VLDL, IDL, LDL, and Lp(a). Each of these particles carries exactly one ApoB molecule. This is not a coincidence of biology but a structural requirement - ApoB is the scaffolding around which these particles are assembled and the ligand through which they bind to LDL receptors for hepatic clearance.2
Because each atherogenic particle carries exactly one ApoB, an ApoB measurement is a direct and unambiguous count of the total number of atherogenic particles in your bloodstream. It captures LDL particles, VLDL particles (elevated in hypertriglyceridemia), IDL particles, and Lp(a) particles - all in a single number. This makes ApoB the most comprehensive and direct available measure of atherogenic particle burden.
Why LDL-C and ApoB Diverge: The Discordance Problem
LDL cholesterol and ApoB are correlated at the population level but frequently discordant at the individual level - and the discordance is clinically consequential. The most common discordant pattern is normal LDL-C with elevated ApoB, which occurs when an individual has a high number of small, cholesterol-poor LDL particles. Each particle carries less cholesterol than a large LDL particle, so the total LDL-C appears normal or even low. But the particle count - and therefore the ApoB - is elevated, reflecting genuinely higher cardiovascular risk.3
This pattern is particularly common in people with metabolic syndrome, insulin resistance, hypertriglyceridemia, type 2 diabetes, and those eating a high-carbohydrate diet that drives VLDL overproduction. It is also common in the 50 to 65 percent of people who are partial non-responders to statin therapy - their LDL-C drops substantially but their particle count does not fall proportionally. Measuring only LDL-C in these individuals gives a false sense of security.
"LDL cholesterol is the cargo. ApoB counts the trucks. It is the trucks that crash into arterial walls, not the cargo itself."
Dr. Peter Attia, longevity physician and author of OutliveApoB vs LDL-C: The Evidence That ApoB Wins
The case for ApoB as a superior cardiovascular risk biomarker rests on multiple lines of evidence. The INTERHEART study, which enrolled 15,152 cases of first myocardial infarction and 14,820 controls across 52 countries, found that the ApoB to ApoA1 ratio was the strongest single lipid risk factor for myocardial infarction - stronger than LDL-C, non-HDL cholesterol, or total cholesterol to HDL ratio - across all ethnic groups, ages, and sexes studied.4
Multiple large meta-analyses and Mendelian randomization studies have confirmed that ApoB more precisely captures cardiovascular risk when LDL-C and ApoB are discordant. The 2019 European Society of Cardiology guidelines explicitly endorsed ApoB as a preferred risk measure when LDL-C may be unreliable, and the 2022 American College of Cardiology/AHA guidelines now include ApoB as an option for risk stratification and treatment target monitoring.
ApoB Target Levels: Standard vs Longevity-Optimized
| ApoB Level | Clinical Classification | Longevity Context | Cardiovascular Risk |
|---|---|---|---|
| <60 mg/dL | Optimal | Longevity target for highest-risk individuals | Lowest observed risk |
| 60-70 mg/dL | Very low | Primary longevity target | Very low risk |
| 70-90 mg/dL | Near optimal | Reasonable if no other risk factors | Low to moderate |
| 90-110 mg/dL | Borderline elevated | Consider intervention | Moderate |
| >110 mg/dL | Elevated | Intervention indicated | Elevated |
How to Lower ApoB
Statins are the most potent available ApoB-lowering agents, reducing ApoB by 30 to 55 percent depending on dose and statin type. High-intensity statins (rosuvastatin 20-40 mg, atorvastatin 40-80 mg) produce the greatest particle count reductions.5 PCSK9 inhibitors (evolocumab, alirocumab) reduce ApoB by an additional 50 to 60 percent on top of statin therapy, producing the lowest ApoB levels achievable pharmacologically - and the outcomes data from the FOURIER and ODYSSEY trials establish that lower is better with no observed lower threshold of benefit down to ApoB levels below 30 mg/dL. Dietary interventions: replacing saturated fat with unsaturated fat reduces LDL-C and ApoB; reducing refined carbohydrates reduces VLDL and particle number in insulin-resistant individuals. Dietary approaches typically reduce ApoB by 10 to 20 percent - meaningful but rarely sufficient alone for people with significantly elevated baseline values.
ApoB is available at Quest Diagnostics, LabCorp, and most commercial labs. It can be ordered by a physician as part of an advanced lipid panel, or self-ordered in most US states through services like Ulta Lab Tests, Walk-In Lab, or Any Lab Test Now for approximately 15 to 25 dollars. There is no fasting requirement for ApoB (unlike triglycerides). Include ApoB in every annual lipid assessment alongside LDL-C, HDL-C, triglycerides, and Lp(a).
References
- 1Grundy SM, et al. "2018 AHA/ACC Guideline on the Management of Blood Cholesterol." JACC. 2019;73(24):e285-e350. [PubMed]
- 2Sniderman AD, et al. "A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk." Circulation: Cardiovascular Quality and Outcomes. 2011. [PubMed]
- 3Cromwell WC, et al. "LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study." Journal of Clinical Lipidology. 2007;1(6):583-592. [PubMed]
- 4Yusuf S, et al. "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study)." Lancet. 2004;364(9438):937-952. [PubMed]
- 5Boekholdt SM, et al. "Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins." JAMA. 2012;307(12):1302-1309. [PubMed]